Table 2.
Risk factors for survival in patients with HIV-associated Burkitt lymphoma
| Overall survival | Progression-free survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Variables | Univariate | Multivariate | Univariate | Multivariate | ||||
| P value | HR | 95% | P* value | P value | HR | 95% | P* value | |
| Male | 0.941 | 0.826 | ||||||
| Age > 40 | 0.077 | 0.277 | ||||||
| Household registration | 0.249 | 0.417 | ||||||
| Primary site | 0.668 | 0.999 | ||||||
| Evaluated LDH | 0.889 | 0.291 | ||||||
| LDH > 3ULN | 0.041 | 2.806 | 1.050–7.497 | 0.040 | 0.108 | |||
| ECOG > 1 | 0.872 | 0.851 | ||||||
| With B symptom | 0.247 | 0.308 | ||||||
| Ann Arbor stage III-IV | 0.835 | 0.140 | ||||||
| BM involvement | 0.397 | 0.539 | ||||||
| CNS involvement | < 0.001 | 5.572 | 2.019–15.375 | 0.001 | < 0.001 | 5.985 | 2.165–16.542 | 0.001 |
| CD4 > 100 cells/μl | 0.302 | 0.522 | ||||||
| HIV plasmaviremia | 0.159 | 0.232 | ||||||
| CD4/CD8 ratio | 0.528 | 0.417 | ||||||
| With bulky disease | 0.325 | 0.136 | ||||||
| Rituximab-containing | 0.562 | 0.392 | ||||||
| Chemotherapy regimens | 0.459 | 0.355 | ||||||
BM, bone marrow; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; * P value was calculated by COX regression and p < 0.05 regarded significant